{"id":3058,"date":"2016-06-22T06:30:00","date_gmt":"2016-06-22T06:30:00","guid":{"rendered":"https:\/\/www.xvivogroup.com\/us\/mfn_news\/lung-cancer-patient-given-chemotherapy-through-in-vivo-lung-perfusion-with-steen-solution\/"},"modified":"2016-06-22T06:30:00","modified_gmt":"2016-06-22T06:30:00","slug":"lung-cancer-patient-given-chemotherapy-through-in-vivo-lung-perfusion-with-steen-solution","status":"publish","type":"mfn_news","link":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/lung-cancer-patient-given-chemotherapy-through-in-vivo-lung-perfusion-with-steen-solution\/","title":{"rendered":"Lung Cancer Patient given Chemotherapy through In Vivo Lung Perfusion with STEEN Solution\u2122"},"content":{"rendered":"<div class=\"mfn-preamble\"><strong>STEEN Solution\u2122 was used for the first time to give localized delivery of a chemotherapy agent to a patient suffering from metastatic lung sarcoma through In-Vivo Lung Perfusion (IVLP).\u00a0 This was also the first time STEEN Solution was used to perfuse a lung on In-Vivo i.e. on a living patient. The aim of the study is to prove safety and evaluate the ability to use STEEN Solution\u2122 to improve isolated tissue therapy.<\/strong><\/div>\n<p><span>A leading hospital enrolled their first patient into a clinical trial to provide chemotherapy to patients suffering from lung sarcomas.\u00a0 According to the 2016 data from the American Cancer Society, soft tissue sarcomas affect approximately 12,310 people annually in the United States and more than 4,990 Americans will die each year of this disease.\u00a0 Of the patients who develop extremity sarcoma, approximately 20% will have isolated pulmonary metastatic disease at some point in the course of their disease.\u00a0 Surgery is the preferred way of treating pulmonary sarcomas but due to micrometastasis, that cannot be seen, the person has a greater than 70% risk of pulmonary recurrence after this surgery. The use of systemic chemotherapy has not been used due to the significant side effects with unproven benefit. With the use of in-vivo lung perfusion the surgeon can shut off the lung from the systemic circulation and give the chemotherapy only to the lung so as not to affect the rest of the body.<\/span><\/p>\n<p><span>\u201cThis is a significant step forward in expanding the capability of IVLP in cancer therapy.\u00a0 <\/span><span>The dosage of chemotherapy given is yet to be determined to give optimal therapy with reduced side effects but this is the beginning of a new chapter in cancer therapy<\/span><span>\u201d, says Magnus Nilsson, CEO of XVIVO Perfusion.<\/span><\/p>\n<\/p>\n<p><span>June 22, 2016<br \/><\/span>Gothenburg<br \/>XVIVO Perfusion AB (publ)<\/p>\n<div class=\"mfn-footer\">\n<p><span>For further information please contact:<\/span><\/p>\n<p><span>Christoffer Rosenblad, CFO, +1 720 616 2101, christoffer.rosenblad@xvivoperfusion.com<br \/>Magnus Nilsson, CEO, +46 31 788 2150, magnus.nilsson@xvivoperfusion.com<\/span><br \/><span>For further information on XVIVO Perfusion\u2019s business, please refer to the company\u2019s website, www.xvivoperfusion.com<\/span><\/p>\n<p><span>The information was submitted for publication on\u00a0June 22, 2016\u00a0at 8:30 a.m.<\/span><\/p>\n<p><span>This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.<\/span><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>STEEN Solution\u2122 was used for the first time to give localized delivery of a chemotherapy agent to a patient suffering&#8230;<\/p>\n","protected":false},"template":"","class_list":["post-3058","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-regulatory-listing","mfn-news-tag-mfn-ci","mfn-news-tag-mfn-ci-other","mfn-news-tag-mfn","mfn-news-tag-mfn-type-ir","mfn-news-tag-mfn-lang-en","mfn-news-tag-mfn-regulatory"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Lung Cancer Patient given Chemotherapy through In Vivo Lung Perfusion with STEEN Solution\u2122 - XVIVO<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.xvivogroup.com\/us\/pressreleases\/lung-cancer-patient-given-chemotherapy-through-in-vivo-lung-perfusion-with-steen-solution\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Lung Cancer Patient given Chemotherapy through In Vivo Lung Perfusion with STEEN Solution\u2122 - XVIVO\" \/>\n<meta property=\"og:description\" content=\"STEEN Solution\u2122 was used for the first time to give localized delivery of a chemotherapy agent to a patient suffering...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.xvivogroup.com\/us\/pressreleases\/lung-cancer-patient-given-chemotherapy-through-in-vivo-lung-perfusion-with-steen-solution\/\" \/>\n<meta property=\"og:site_name\" content=\"United States\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/lung-cancer-patient-given-chemotherapy-through-in-vivo-lung-perfusion-with-steen-solution\\\/\",\"url\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/lung-cancer-patient-given-chemotherapy-through-in-vivo-lung-perfusion-with-steen-solution\\\/\",\"name\":\"Lung Cancer Patient given Chemotherapy through In Vivo Lung Perfusion with STEEN Solution\u2122 - XVIVO\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/#website\"},\"datePublished\":\"2016-06-22T06:30:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/lung-cancer-patient-given-chemotherapy-through-in-vivo-lung-perfusion-with-steen-solution\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/lung-cancer-patient-given-chemotherapy-through-in-vivo-lung-perfusion-with-steen-solution\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/lung-cancer-patient-given-chemotherapy-through-in-vivo-lung-perfusion-with-steen-solution\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Lung Cancer Patient given Chemotherapy through In Vivo Lung Perfusion with STEEN Solution\u2122\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/#website\",\"url\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/\",\"name\":\"United States\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Lung Cancer Patient given Chemotherapy through In Vivo Lung Perfusion with STEEN Solution\u2122 - XVIVO","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/lung-cancer-patient-given-chemotherapy-through-in-vivo-lung-perfusion-with-steen-solution\/","og_locale":"en_US","og_type":"article","og_title":"Lung Cancer Patient given Chemotherapy through In Vivo Lung Perfusion with STEEN Solution\u2122 - XVIVO","og_description":"STEEN Solution\u2122 was used for the first time to give localized delivery of a chemotherapy agent to a patient suffering...","og_url":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/lung-cancer-patient-given-chemotherapy-through-in-vivo-lung-perfusion-with-steen-solution\/","og_site_name":"United States","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/lung-cancer-patient-given-chemotherapy-through-in-vivo-lung-perfusion-with-steen-solution\/","url":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/lung-cancer-patient-given-chemotherapy-through-in-vivo-lung-perfusion-with-steen-solution\/","name":"Lung Cancer Patient given Chemotherapy through In Vivo Lung Perfusion with STEEN Solution\u2122 - XVIVO","isPartOf":{"@id":"https:\/\/www.xvivogroup.com\/us\/#website"},"datePublished":"2016-06-22T06:30:00+00:00","breadcrumb":{"@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/lung-cancer-patient-given-chemotherapy-through-in-vivo-lung-perfusion-with-steen-solution\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.xvivogroup.com\/us\/pressreleases\/lung-cancer-patient-given-chemotherapy-through-in-vivo-lung-perfusion-with-steen-solution\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/lung-cancer-patient-given-chemotherapy-through-in-vivo-lung-perfusion-with-steen-solution\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.xvivogroup.com\/us\/"},{"@type":"ListItem","position":2,"name":"Lung Cancer Patient given Chemotherapy through In Vivo Lung Perfusion with STEEN Solution\u2122"}]},{"@type":"WebSite","@id":"https:\/\/www.xvivogroup.com\/us\/#website","url":"https:\/\/www.xvivogroup.com\/us\/","name":"United States","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.xvivogroup.com\/us\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/mfn_news\/3058","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/media?parent=3058"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}